Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

7.05USD
4:00pm EDT
Change (% chg)

$0.05 (+0.71%)
Prev Close
$7.00
Open
$6.95
Day's High
$7.07
Day's Low
$6.95
Volume
6,549
Avg. Vol
12,589
52-wk High
$7.35
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Q4 loss per share $0.29
Wednesday, 1 Mar 2017 04:01pm EST 

Kindred Biosciences Inc : Kindred biosciences announces fourth quarter and year-end 2016 financial results . Q4 loss per share $0.29 .Q4 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz
Monday, 6 Feb 2017 09:00am EST 

Kindred Biosciences Inc : Kindred biosciences receives early approval of effectiveness technical section from fda for mirataz™ new animal drug application . Kindred biosciences inc - has received a technical section complete letter for effectiveness from u.s. Food and drug administration . Kindred biosciences inc says expect approval of mirataz in second half of 2017 assuming no unforeseen delays in review process .Kindred biosciences inc - basis for complete letter was a multicenter, randomized, double-blind, placebo-controlled pivotal field study.  Full Article

Kindred Biosciences gets approval from FDA for new animal drug application
Tuesday, 4 Oct 2016 04:01pm EDT 

Kindred Biosciences Inc : Kindred Biosciences receives approval of effectiveness technical section from fda for zimeta new animal drug application . Kindredbio is in process of responding to first round of review by fda on safety technical section .Kindred Biosciences Inc says expects approval of Zimeta in first half of 2017 if FDA review process is rapid.  Full Article

Kindred Biosciences submits final major NADA technical section for Safety for Mirataz to FDA
Friday, 30 Sep 2016 09:01am EDT 

Kindred Biosciences Inc : Kindred Biosciences submits final major New Animal Drug Application technical section for Safety for Mirataz to FDA and launches KindredBio Equine website .In target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified.  Full Article

Kindred Biosciences submits new drug application to FDA
Monday, 22 Aug 2016 04:01pm EDT 

Kindred Biosciences Inc [KIN.O] : Kindred Biosciences submits new animal drug application technical section for effectiveness for mirataz to FDA .Company plans to submit safety technical section in Q3 of 2016.  Full Article

Kindred Biosciences posts Q2 loss per share $0.25
Monday, 8 Aug 2016 04:01pm EDT 

Kindred Biosciences Inc : Kindred Biosciences announces second quarter 2016 financial results . Q2 loss per share $0.25 .For 2016 calendar year company reiterates its previous guidance for operating expenses to be in range of $24 million to $26 million.  Full Article

Kindred Biosciences submits Zimeta (KIND-012) new animal drug application technical section for effectiveness to FDA
Thursday, 11 Feb 2016 04:01pm EST 

Kindred Biosciences:The submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta(tm) (dipyrone injection, KIND-012).Positive topline results from the pivotal field study (KB0120) of Zimeta for the control of pyrexia (fever) in horses were recently reported by the Company.  Full Article

Kindred Biosciences submits KIND-012 new animal drug application technical section for chemistry, manufacturing, and controls to FDA
Thursday, 17 Dec 2015 09:02am EST 

Kindred Biosciences, Inc:Announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012.Positive topline results from the pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses were recently reported by the Company.  Full Article

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates
Monday, 16 Nov 2015 08:30am EST 

Kindred Biosciences Inc :Announces positive results from pivotal study of kind-012 for pyrexia in horses, and provides other product updates.Says kind-012 study meets primary endpoint with p <0.0001.Says data to be filed with the FDA for approval; sentikind study misses primary endpoint.Says sentikind study misses primary endpoint.Says based on preliminary review of the safety data, the drug appears to be well tolerated.Positive topline results from its pivotal field study (kb0120) of kind-012 for the control of pyrexia (fever) in horses.Pivotal field study of sentikind for control of pain following orthopedic surgery in dogs did not meet primary endpoint.Says results from the pivotal study of kind-010 for management of weight loss in cats are expected by middle of 2016.Will be initiating a pilot field study of feline epo early 2016, on heels of a positive laboratory pilot feline epo pilot study.  Full Article

More From Around the Web

BRIEF-Kindred Biosciences Q4 loss per share $0.29

* Kindred biosciences announces fourth quarter and year-end 2016 financial results